EPS: As of FY2025 Q2, the actual value is USD -0.12.

EBIT: As of FY2025 Q2, the actual value is USD -4.093 M.

Segment Revenue

• The company did not generate any revenue for the three and six months ended June 30, 2025, and 2024.

Operational Metrics

• Net Loss: For the three months ended June 30, 2025, the net loss was $4,093,231, compared to $451,639 for the same period in 2024. For the six months ended June 30, 2025, the net loss was $6,327,213, compared to $1,123,683 for the same period in 2024.
• Operating Expenses: Operating expenses for the three months ended June 30, 2025, were $1,892,852, compared to $395,607 for the same period in 2024. For the six months ended June 30, 2025, operating expenses were $3,479,820, compared to $817,652 for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: For the six months ended June 30, 2025, net cash used in operating activities was $3,522,178, compared to $929,399 for the same period in 2024.
• Net Cash Provided by Financing Activities: For the six months ended June 30, 2025, net cash provided by financing activities was $11,889,383, compared to $1,895,424 for the same period in 2024.

Unique Metrics

• Share-based Compensation: The company recorded share-based compensation of $390,195 for the three months ended June 30, 2025, and $885,695 for the six months ended June 30, 2025.

Future Outlook and Strategy

• Core Business Focus: The company is focused on developing essential medicines for chronic diseases, including cancer, cardiovascular, and neurodegenerative disorders, using its licensed platforms and proprietary technologies.
• Non-Core Business: The company terminated the Share Exchange Agreement to acquire SB Security Holdings, LLC, indicating a focus on its core business areas.
• Priority: The company is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities to continue its development plans and operations.